Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy

Cytokine-based immunotherapy is a promising field in the cancer treatment, since cytokines, as proteins of the immune system, are able to modulate the host immune response toward cancer cell, as well as directly induce tumor cell death. Since a low dose monotherapy with some cytokines has no significant therapeutic results and a high dose treatment leads to a number of side effects caused by the pleiotropic effect of cytokines, the problem of understanding the influence of cytokines on the immune cells involved in the pro- and anti-tumor immune response remains a pressing one. Immune system cells carry CD makers on their surface which can be used to identify various populations of cells of the immune system that play different roles in pro- and anti-tumor immune responses. This review discusses the functions and specific CD markers of various immune cell populations which are reported to participate in the regulation of the immune response against the tumor. The results of research studies and clinical trials investigating the effect of cytokine therapy on the regulation of immune cell populations and their surface markers are also discussed. Current trends in the development of cancer immunotherapy, as well as the role of cytokines in combination with other therapeutic agents, are also discussed

Women's Experiences of Sexual Problems After Cervical Cancer Treatment: Lessons From Indonesian Women

Cervical cancer remains the most common cancer among women. It is the second major cause of women’s deaths in Asia as well as in Indonesia. Cervical cancer treatment also raises issues of long-term physical, psychological, sexual, and social adaptation. The purpose of the study was to describe and to interpret the experiences of Indonesian women who have experienced sexual dysfunction after cervical cancer treatment. Thirteen Indonesian women who were participated in this study described their experiences on the first to two years after cervical cancer treatment. Data were collected through in-depth interviews. Four themes were identified (1) physical and psychological sexual complaints after cancer treatment; (2) negative effects of cancer treatment towards intimate relationship with their spouse; (3) efforts to overcome sexual problems; and (4) women’s needs for help to improve their sexual health. These studyfindings offer providing new insights into the experiences of Indonesian women with sexual health problems following cervical cancer treatment. This study can provide nurses and other health care providers with better understanding of the experiences, concern and needs of the cancer survivors

Immune Checkpoints in Cancer Treatment

Despite the human immune system, cancer thrives in an extremely hostile environment. Cancer is the second most common cause of death in the U.S. with about 600,000 deaths every year, and cancer is expected to surpass heart disease as the most common cause of death in the U.S. Immune checkpoint inhibitors are a novel and promising therapeutic for treating cancer in its late stages

Emerging evidence for CHFR as a cancer biomarker : from tumor biology to precision medicine

Novel insights in the biology of cancer have switched the paradigm of a "one-size-fits-all" cancer treatment to an individualized biology-driven treatment approach. In recent years, a diversity of biomarkers and targeted therapies has been discovered. Although these examples accentuate the promise of personalized cancer treatment, for most cancers and cancer subgroups no biomarkers and effective targeted therapy are available. The great majority of patients still receive unselected standard therapies with no use of their individual molecular characteristics. Better knowledge about the underlying tumor biology will lead the way toward personalized cancer treatment. In this review, we summarize the evidence for a promising cancer biomarker: checkpoint with forkhead and ring finger domains (CHFR). CHFR is a mitotic checkpoint and tumor suppressor gene, which is inactivated in a diverse group of solid malignancies, mostly by promoter CpG island methylation. CHFR inactivation has shown to be an indicator of poor prognosis and sensitivity to taxane-based chemotherapy. Here we summarize the current knowledge of altered CHFR expression in cancer, the impact on tumor biology and implications for personalized cancer treatment

UVA Assisted 4-Thiothymidine for Cancer Treatment

This article reviews the developments of 4-thiothymidine analogues, assisted with UVA light, as a novel cancer therapy. First, the key points on synthetic chemistry, photochemistry and cellular toxicity of 4-thiothymidine are summarized. As the chemical structure of 4-thiothymidine is very similar to that of its parent thymidine, thus 4-thiothymidine can be readily incorporated into cellular DNA, and with the help of thymidine kinase, much more preferably into cancerous DNA. Unlike thymidine, 4-thiothymdine can absorb strongly in UVA (longer wavelengths of UV) light. Thus UVA-assisted 4-thiothymidine offers an effective cancer treatment. Some underlying mechanisms of action by 4-thiothymidine/UVA and compares this cancer approach with the commonly used photodynamic therapy are discussed. The various interactions between 4-thiothymidine with human serum albumin are introduced. Finally, a short conclusion on the past efforts and a brief prospect for future work in this exciting research field are given

RNA Vaccine: novel approach for cancer treatment

Cancer is still an unsolved puzzle and a major cause of mortality and morbidity in the world. Today, about one in every thousand people is dying due to cancer. No effective agent has yet been found which can cure cancer in its metastatic stage. However, attempts in the shape of chemotherapy, immunotherapy and vaccines are made worldwide to find a remedy through a proper regimen. In continuation, tumor specific mRNA has been introduced as part of vaccines in recent days. It is mostly used in transfection with Dendritic Cells (DCs) for better effectiveness and safety. The DCs are selected for transfection because they are highly potent Antigen Presenting Cells (APCs) with the ability to take up & process tumor antigen in peripheral blood & tissues and can also migrate to the draining lymph nodes to present antigen to naïve T lymphocytes & induce the immune response.
Although initially the RNA vaccination was administered alone, due to its unstable and easily degradable nature, it was found to be quite less effective, which led it to be used in combination with some stability enhancers’ viz. RNA packaging in liposomes. They not only increased its stability, but even worked as active immune stimulators as well. RNA could remain stable. Although it showed significant promise in cancer treatment, immune suppression was noticed after vaccination. To enhance the effectiveness it is now being used in combination with few drugs viz. SUNITINIB which can reduce the suppressive effect of suppressor cells. It might be a good choice for combined therapy with RNA vaccine.
&#xa

Repurposing metformin for cancer treatment: current clinical studies.

In recent years, several studies have presented evidence suggesting a potential role for metformin in anti-cancer therapy. Preclinical studies have demonstrated several anticancer molecular mechanisms of metformin including mTOR inhibition, cytotoxic effects, and immunomodulation. Epidemiologic data have demonstrated decreased cancer incidence and mortality in patients taking metformin. Several clinical trials, focused on evaluation of metformin as an anti-cancer agent are presently underway. Data published from a small number of completed trials has put forth intriguing results. Clinical trials in pre-surgical endometrial cancer patients exhibited a significant decrease in Ki67 with metformin monotherapy. Another interesting observation was made in patients with breast cancer, wherein a trend towards improvement in cancer proliferation markers was noted in patients without insulin resistance. Data on survival outcomes with the use of metformin as an anti-cancer agent is awaited. This manuscript will critically review the role of metformin as a potential cancer treatment